

What we claim is:

1. An isolated polynucleotide comprising a member selected from the group consisting of:
 - (a) a polynucleotide encoding the polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:2;
 - (b) a polynucleotide encoding the polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:4;
 - (c) a polynucleotide capable of hybridizing to and which is at least identical to the polynucleotide of (a) or (b);
 - (d) a polynucleotide fragment of the polynucleotide of (a), (b) or (c).
2. The polynucleotide of claim 1, wherein the polynucleotide is DNA, RNA or genomic DNA.
3. The polynucleotide of claim 1 which encodes the polypeptide comprising the amino acid sequence of SEQ ID NO:2.
4. The polynucleotide of claim 1 which encodes the polypeptide comprising the amino acid sequence of SEQ ID NO:4.
5. The polynucleotide of claim 1, comprising the nucleotide sequence as set forth in SEQ ID NO:1.
6. The polynucleotide of claim 1, comprising the nucleotide sequence as set forth in SEQ ID NO:3.
7. A vector containing the polynucleotide of claim 1.
8. A host cell transformed or transfected with vector of claim 7.
9. A process for producing a polypeptide comprising: expressing from the host cell of claim 8 the polypeptide encoded by said polynucleotide.
10. A polypeptide comprising a member selected from the group consisting of:
 - (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments thereof which retain the biological activity of said polypeptide; and
 - (ii) a polypeptide having the deduced amino acid sequence of SEQ ID NO:4 and fragments thereof which retain the biological activity of said polypeptide.
11. An antibody against the polypeptide of claim 10.

12. A method for treating an individual in need of an increased level of IL-17RLM polypeptide activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an isolated IL-17RLM polypeptide of claim 10 or an agonist thereof.
13. The method of claim 12, wherein the individual has a neuron disease.
14. A method for treating an individual in need of a decreased level of IL-17RLM polypeptide activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of IL-17RLM antagonist.
15. The method of claim 14, wherein the individual has an autoimmune disease including rheumatoid arthritis or asthma.
16. A diagnostic method comprising determining the level of the polypeptide of claim 10 in a sample of an individual, wherein an increased level of such polypeptide is an indicative of the possible presence of a kidney- or testis-related carcinoma in said individual.